（文章来源：证券日报） 证券日报网讯 9月12日晚间，泰林生物发布公告称，公司全资子公司泰林医疗器械近期共取得了1项专 利证书，专利名称为"一种微生物限度检验自动化设备"。 ...

泰林生物公告，全资子公司泰林医疗器械于近期取得1项实用新型专利证书。该专利名称为"一种微生物 限度检验自动化设备"，申请号为2024218453749，授权公告日为2025年9月5日。该专利的取得不会对近 期生产经营产生重大影响，但有利于公司进一步完善知识产权保护体系，发挥自主知识产权优势，形成 持续创新机制，提升核心竞争力。 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-070 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 医疗器械有限公司（以下简称"泰林医疗器械"）于近期共取得了 1 项专利证书， 具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种微生物限度检验自 | 实用新型 | 2024218453749 | 2025/9/5 | 泰林医疗器械 | | | 动化设备 | | | | | 浙江泰林生物技术股份有限公司 关于取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上述专利的取得不会对公司及全资子公司泰林医疗器械近期生产经营产生 重大影响，但有利于公司及全资子公司泰林医疗器械进一步完善知识产权保护体 系，发挥自主知识产权优势，并形成持续创新机制，保持技术领先地位，提升核 心竞争力。 特此公告。 浙江泰林生物技术股份有限公司董事会 2025 年 9 月 12 日 ...

Group 1 - The core viewpoint of the news is that Tailin Bio has seen a stock price increase of 5.07%, reaching 33.15 CNY per share, with a total market capitalization of 4.018 billion CNY [1] - Tailin Bio, established on January 8, 2002, and listed on January 14, 2020, specializes in the research, manufacturing, and sales of microbial detection and control technology systems, as well as organic analysis instruments [1] - The main revenue composition of Tailin Bio includes 41.12% from microbial detection technology products, 40.78% from sterile production and contamination control equipment, 11.15% from organic analysis technology products, and 6.95% from other sources [1] Group 2 - The fund "Noan Multi-Strategy Mixed A" (320016) has entered the top ten circulating shareholders of Tailin Bio, holding 511,200 shares, which is 0.67% of the circulating shares [2] - The fund has achieved a year-to-date return of 61.81%, ranking 429 out of 8,174 in its category, and a one-year return of 121.96%, ranking 230 out of 7,981 [2] - The fund manager, Kong Xianzheng, has a tenure of 4 years and 291 days, with a best fund return of 76.44% during his management [3] Group 3 - The fund "Noan Multi-Strategy Mixed A" increased its holdings in Tailin Bio by 286,000 shares in the second quarter, making it the fourth-largest holding in the fund [4] - The current floating profit from the investment in Tailin Bio is approximately 817,900 CNY [4]

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 1、目前的研发投入聚焦在哪些领域的新产品？ 答：（1）围绕着微生物检测和控制领域，具体在工业微 生物产品线和水生态监测产品线；（2）围绕生命科学核心需 求，重点聚焦医药健康产品质控领域、创新药生产保障领域、 重大疾病诊疗药物安全领域三大方向；（3）光腔衰荡光谱分 析技术、微粒激光成像及识别等。 2、看到公司有参加半导体行业分析会，公司产品在半导 体行业的应用情况？ 编号：2025003 | 投资者关系活动 | 特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 永赢基金：张晓榕 | | 人员姓名 | 华宝基金：张金涛、魏扬帆 | | | 中信证券：张斌斌 | | 时间 | 2025 年 9 月 9 日下午 14:00 | | 地点 | 浙江省杭州市滨江区南环路 2930 号 12F 小会议室 | | 上市公司接待人 | 董事会秘书、 ...

9月9日，泰林生物跌5.05%，截至发稿，报31.77元/股，成交7923.84万元，换手率3.17%，总市值38.50 亿元。 资料显示，浙江泰林生物技术股份有限公司位于浙江省杭州市滨江区南环路2930号，成立日期2002年1 月8日，上市日期2020年1月14日，公司主营业务涉及微生物检测与控制技术系统产品、有机物分析仪器 等制药装备的研发、制造和销售。主营业务收入构成为：无菌生产与污染控制设备系列产品47.03%， 微生物检测技术系列产品35.70%，其他(补充)9.96%，有机物分析技术系列产品7.32%。 从泰林生物十大流通股东角度 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模13.99亿。今年以来收益61.14%，同类 排名335/8179；近一年收益123.1%，同类排名161/7984；成立以来收益211%。 诺安多策略混合A（320016）基金经理为孔宪政、王海畅。 截至发稿，孔宪政累计任职时间4年288天，现任基金资产总规模46.07亿元，任职期间最佳基金回报 72.32%， 任职期间最差基金回报-16.74%。 王海畅累计任职时间3年50天，现任基金资产总规模25 ...

Core Viewpoint - TaiLin Bio's financial performance shows a mixed picture with a decline in total revenue but a significant increase in net profit and profitability metrics [1] Financial Performance Summary - Total revenue for the first half of 2025 was 146 million yuan, a decrease of 6.69% year-on-year [1] - Net profit attributable to shareholders reached 13.54 million yuan, an increase of 105.76% year-on-year [1] - In Q2 2025, total revenue was 78.89 million yuan, up 3.42% year-on-year, while net profit was 10.01 million yuan, up 1312.58% year-on-year [1] - Gross margin improved to 51.92%, a year-on-year increase of 12.08%, and net margin rose to 9.15%, up 143.76% year-on-year [1] - Total operating expenses (selling, administrative, and financial) amounted to 30.20 million yuan, accounting for 20.71% of revenue, a decrease of 7.81% year-on-year [1] - Earnings per share increased to 0.11 yuan, a rise of 83.33% year-on-year, while operating cash flow per share improved to 0.03 yuan, up 110.38% year-on-year [1] Asset and Liability Overview - Cash and cash equivalents decreased to 198 million yuan, down 34.03% year-on-year [1] - Accounts receivable increased to 46.92 million yuan, a rise of 4.47% year-on-year [1] - The company reported a return on invested capital (ROIC) of 2.12% for the previous year, indicating weak capital returns [1] Investment Insights - The company’s business model relies heavily on research and marketing efforts, necessitating a deeper analysis of these driving factors [1] - The largest fund holding TaiLin Bio is the Nuoan Multi-Strategy Mixed A fund, which has increased its holdings [2]

Group 1 - The company held meetings on August 27, 2025, to review and approve the profit distribution plan for the first half of 2025, which will be submitted to the third extraordinary general meeting of shareholders for approval [1][2] - The proposed profit distribution plan includes a cash dividend of 1 yuan (including tax) for every 10 shares, with no stock dividends or capital reserve transfers [2][3] - The company's net profit for the first half of 2025 was -6,744,251.38 yuan, and the actual distributable profit as of June 30, 2025, was 96,821,547.99 yuan [2][3] Group 2 - The independent directors believe the profit distribution plan considers the company's operational status, future development, and reasonable shareholder returns, aligning with the company's articles of association and legal regulations [1][2] - The supervisory board agrees that the profit distribution plan takes into account the company's profitability and funding needs, ensuring it does not harm the overall interests of the company and its shareholders [2][3] - The cash dividend plan is deemed reasonable and aligns with the company's growth and operational scale, ensuring that it will not adversely affect the company's liquidity or long-term development [4]

Group 1 - The company, Tailin Biotech, announced the approval of several proposals during the ninth meeting of its fourth board of directors, including the profit distribution plan for the first half of 2025 [2]

Group 1 - The company announced the approval of the full text and summary of the 2025 semi-annual report during the eighth meeting of the fourth supervisory board [2]